Recombinant factor XIII: A safe and novel treatment for congenital factor XIII deficiency

Blood

Volumn 119, Issue 22, 2012, Pages 5111-5117

  Inbal, Aida ^a   Oldenburg, Johannes ^b   Carcao, Manuel ^c   Rosholm, Anders ^d   Tehranchi, Ramin ^d   Nugent, Diane ^e  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d NOVO NORDISK A S   (Denmark)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; CATRIDECACOG;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 13A DEFICIENCY; BLOOD CLOTTING FACTOR DEFICIENCY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LEUKOPENIA; LIMIT OF DETECTION; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHOOL CHILD;

EID: 84861796622     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-386045     Document Type: Article

References (21)

1. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost. 2009;35(4):426-438.
2. Ivaskevicius V, Seitz R, Kohler HP, et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost. 2007;97(6):914-921.
3. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia. 2002;8(3):308-321.
4. Biswas A, Ivaskevicius V, Seitz R, Thomas A, Oldenburg J. An update of the mutation profile of Factor 13 A and B genes. Blood Rev. 2011;25(5): 193-204.
5. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol. 1998;5(6):372-375.
6. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. 1999;107(3):468-484.
7. Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006;108(1):57-62.
8. Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L, on behalf of the Factor XIII and Fibrinogen SSC. Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9(7):1404-1406.
9. Lawrie AS, Green L, Mackie IJ, et al. Factor XIII-an under diagnosed deficiency-are we using the right assays? J Thromb Haemost. 2010;8(11): 2478-2482.
10. Jennings I, Kitchen S, Woods TA, Preston FE; UK NEQAS. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost. 2003;1(12):2603-2608.
11. Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost. 1995;74(2):622-625.
12. Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia. 2010;16(2):316-321.
13. Yoshida S, Fukue H, Sugimura D, et al. Efficiency of intermittent prophylactic factor XIII substitution in congenital factor XIII A subunit deficiency. Japanese Journal of Transfusion Medicine. 1996; 42(4):173-177.
14. Dreyfus M, Barrois D, Borg JY, et al; Groupe d'Etudes Francophone du FXIII. Successful long-term replacement therapy with FXIII concentrate (Fibrogammin P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost. 2011;9(6):1264-1266.
15. Gouw SC, Van Der Bom JG, Van Den Berg HM, et al. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia. 2011;17(2):275-281.
16. Maclean PS, Richards M, Williams M, et al; Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia. 2011; 17(2):282-287.
17. Acharya SS, Coughlin A, Dimichele DM; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrino-genemias. J Thromb Haemost. 2004;2(2):248-256.
18. Rivard GE, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia. 2003;9(6):711-716.
19. Seiving B, Henriksson P, Stenberg P, Nilsson IM. A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency. Br J Haematol. 1992;82(2):414-416.
20. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost. 2003;1(12): 2548-2553.
21. Batlle J, Gómez E, Rendal E, et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol. 1996;72(5): 321-326.